Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis

Breast Cancer Research and Treatment

Volumn 131, Issue 2, 2012, Pages 357-369

  Wang, Yuting ^a   Zhang, Chengpeng ^a   Liu, Jianjun ^a   Huang, Gang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

18F FDG PET; Breast cancer; Meta analysis; Prediction; Response; Therapy

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; LETROZOLE; METHOTREXATE; PACLITAXEL DERIVATIVE; PREDNISONE; TRASTUZUMAB; VINCRISTINE;

ACCURACY; ADJUVANT THERAPY; BREAST CANCER; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; META ANALYSIS; METHODOLOGY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PUBLICATION BIAS; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856212121     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1780-z     Document Type: Review

References (35)

1. AC Wolff DN Davidson 2000 Primary systemic therapy in operable breast cancer J Clin Oncol 18 1558 1569 10735905 1:STN:280:DC%2BD3c3gtVGisg%3D%3D (Pubitemid 30205403)
2. P Rastogi SJ Anderson HD Bear CE Geyer MS Kahlenberg A Robidoux RG Margolese JL Hoehn, et al. 2008 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 778 785 18258986 10.1200/JCO.2007.15.0235 (Pubitemid 351264391)
3. SS Norbert Avril R Roylance 2009 Response to therapy in breast cancer J Nucl Med 50 55 63 10.2967/jnumed.108.057240
4. N Wolmark, et al. 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102 11773300
5. R Rouzier JM Extra J Klijanienko MC Falcou B Asselain A Vincent-Salomon, et al. 2002 Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes J Clin Oncol 20 1304 1310 11870173 10.1200/JCO.20.5.1304 (Pubitemid 34177437)
6. A Berriolo-Riedinger C Touzery JM Riedinger M Toubeau B Coudert L Arnould C Boichot A Cochet P Fumoleau F Brunotte 2007 [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy Eur J Nucl Med Mol Imaging 34 1915 1924 17579854 10.1007/s00259-007-0459-5 1:CAS:528:DC%2BD2sXhtlyiurzL (Pubitemid 350212117)
7. SC Partridge JE Gibbs Y Lu LJ Esserman D Sudilovsky NM Hylton 2002 Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy AJR Am J Roentgenol 179 1193 1199 12388497 (Pubitemid 35204372)
8. ME Straver TS Aukema RA Olmos EJ Rutgers KG Gilhuijs ME Schot WV Vogel MJ Peeters 2010 Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients Eur J Nucl Med Mol Imaging 37 1069 1076 20130860 10.1007/s00259-009-1343-2
9. JH Choi HI Lim SK Lee WW Kim SM Kim E Cho EY Ko BK Han YH Park JS Ahn YH Im JE Lee, et al. 2010 The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging J Surg Oncol 102 392 397 19877158 10.1002/jso.21424
10. EL Rosen TG Turkington MS Soo JA Baker RE Coleman 2005 Detection of primary breast carcinoma with a dedicated, large-field-of-view FDG PET mammography device: initial experience Radiology 234 527 534 15671006 10.1148/radiol.2342040654 (Pubitemid 40139925)
11. P Whiting AW Rutjes JB Reitsma PM Bossuyt J Kleijnen 2003 The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews BMC Med Res Methodol 3 25 14606960 10.1186/1471-2288-3-25
12. JP Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses Brit Med J 327 557 560 12958120 10.1136/bmj.327.7414.557 (Pubitemid 37088507)
13. JB Reitsmaa AS Glas AW Rutjes RJ Scholten PM Bossuyta AH Zwindermana 2005 Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews J Clin Epidemiol 58 982 990 10.1016/j.jclinepi. 2005.02.022 (Pubitemid 41316441)
14. F Song KS Khan J Dinnes AJ Sutton 2002 Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy Int J Epidemiol 31 1 88 95 11914301 10.1093/ije/31.1.88 (Pubitemid 34284907)
15. JS Park WK Moon CY Lyou N Cho KW Kang JK Chung 2011 The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography Acta Radiol 52 21 28 21498321 10.1258/ar.2010.100142
16. C Rousseau A Devillers M Campone L Campion L Ferrer C Sagan M Ricaud B Bridji F Kraeber-Bodéré 2011 FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients Eur J Nucl Med Mol Imaging 38 1029 1036 21308372 10.1007/s00259-011-1735-y 1:CAS:528:DC%2BC3MXmtFaqt7Y%3D
17. J Dose-Schwarz R Tiling S Avril-Sassen S Mahner A Lebeau C Webe M Schwaiger F Jänicke M Untch N Avril 2010 Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer Br J Cancer 102 35 41 19920815 10.1038/sj.bjc.6605427 1:STN:280:DC%2BC3c%2FgslSksA%3D%3D
18. SY Jung S Ki-Kim N Byung-Ho SY Min SJ Lee C Park Y Kwon EA Kim KL Ko IH Park KS Lee KH Shin, et al. 2010 Prognostic impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy Ann Surg Oncol 17 247 253 19777177 10.1245/s10434-009-0710-3
19. ME Schneider-Kolsky S Hart J Fox P Midolo J Stuckey M Hofman V Ganju 2010 The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET Breast Cancer Res 12 R37 20565953 10.1186/bcr2591
20. AA Martoni C Zamagni S Quercia M Rosati N Cacciari A Bernardi A Musto S Fanti D Santini M Taffurelli 2010 Early 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy Cancer 115 805 813 10.1002/cncr.24820
21. Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J (2010) Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. doi: 10.1007/s12282-010-0212-y
22. R Prati CA Minami JA Gornbein N Debruhl D Chung D Pharm HR Chang 2009 Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy Cancer 115 1194 1202 19156919 10.1002/cncr.24154 1:CAS:528:DC%2BD1MXktlKns7c%3D
23. A Kumar R Kumar V Seenu SD Gupta M Chawla A Malhotra SN Mehta 2009 The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol 19 6 1347 1357 19214522 10.1007/s00330-009-1303-z
24. J Dose-Schwarz R Tiling S Sassen S Mahner S Kahlert N Harbeck A Lebeau W Brenner M Schwaiger F Jaenicke N Avril 2009 Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose J Clin Oncol 27 535 541 10.1200/JCO.2008.17.2650
25. GM McDermott A Welch RT Staff FJ Gilbert L Schweiger SI Semple K Tim AD Smith AW Hutcheon ID Miller IC Smith SD Heys 2007 Monitoring primary breast cancer throughout chemotherapy using FDG-PET Breast Cancer Res Treat 102 75 84 16897427 10.1007/s10549-006-9316-7 1:CAS:528:DC%2BD2sXhslCltrg%3D (Pubitemid 46294965)
26. C Rousseau A Devillers C Sagan L Ferrer B Bridji L Campion M Ricaud E Bourbouloux I Doutriaux M Clouet D Berton-Rigaud C Bouriel, et al. 2006 Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F] fluorodeoxyglucose positron emission tomography J Clin Oncol 24 5366 5372 17088570 10.1200/JCO.2006.05.7406 (Pubitemid 46623167)
27. SJ Kim SK Kim ES Lee J Ro Sh Kang 2004 Predictive value of [18F]FDG PET for pathological response of breast cancer to neoadjuvant chemotherapy Ann Oncol 15 1352 1357 15319241 10.1093/annonc/mdh345 (Pubitemid 39295023)
28. BC Smith AW Hutcheon ID Miller S Payne F Chilcott S Waikar T Whitaker AK Ah-See O Eremin SD Heys FJ Gilbert, et al. 2000 Positron emission tomography using [18F]-fluorodeoxy-d-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676 1688 10764428 1:STN:280:DC%2BD3c3islyjsg%3D%3D (Pubitemid 30220546)
29. M Schelling N Avril J Nährig W Kuhn W Römer D Sattler M Werner J Dose F Jänicke H Graeff M Schwaiger 2000 Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689 1695 10764429 1:STN:280:DC%2BD3c3islyjsw%3D%3D (Pubitemid 30220547)
30. P Bassa EE Kim T Inoue FC Wong M Korkmaz DJ Yang WH Wong KW Hicks AU Buzdar DA Podoloff 1996 Evaluation of preoperative chemotherapy using PET with fluorine 18-fluorodeoxyglucose in breast cancer J Nucl Med 37 931 938 8683314 1:CAS:528:DyaK28Xkt1KlsL4%3D (Pubitemid 126447124)
31. RL Wahl H Jacene Y Kasamon MA Lodge 2009 From RECIST to PERCIST: evolving considerations for pet response criteria in solid tumors J Nucl Med 50 122S 150S 19403881 10.2967/jnumed.108.057307 1:CAS:528:DC%2BD1MXmtFahtr8%3D
32. WA Weber 2009 Assessing tumor response to therapy J Nucl Med 50 1S 10S 19380403 10.2967/jnumed.108.057174 1:CAS:528:DC%2BD1MXmtFahsb4%3D
33. H Young R Baum U Cremerius K Herholz O Hoekstra AA Lammertsma J Pruim P Price 1999 Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations Eur J Cancer 35 1773 1782 10673991 10.1016/S0959-8049(99)00229- 4 1:STN:280:DC%2BD3c7jvV2ntA%3D%3D (Pubitemid 29512308)
34. AF Schott MA Roubidoux MA Helvie DF Hayes CG Kleer LA Newman LJ Pierce KA Griffith S Murray KA Hunt, et al. 2005 Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy Breast Cancer Res Treat 92 231 238 16155794 10.1007/s10549-005-2510-1 1:CAS:528:DC%2BD2MXpvV2gsLo%3D (Pubitemid 41282819)
35. J Emmering NC Krak JJ Van der Hoeven MD Spreeuwenberg JW Twisk S Meijer HM Pinedo OS Hoekstra 2008 Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology Ann Oncol 19 1573 1577 18552360 10.1093/annonc/mdn185 1:STN:280: DC%2BD1crjtVeksg%3D%3D